Search

XI'AN, China, June 9, 2022 /PRNewswire/ -- Interferons are proteins that constitute an important part of our natural defense systems. These proteins also exhibit a remarkable antiviral activity. The recombinant [...]

WASHINGTON, Feb. 2, 2021 /PRNewswire/ -- Unity Health Care (Unity) proudly announces it has achieved accreditation through Accreditation Commission for Health Care (ACHC) for the specialty pharmacies at Unity Parkside [...]

Four real-world studies presented at the Annual Liver Meeting of the American Association for the Study of Liver Diseases WASHINGTON, Nov. 8, 2019 /PRNewswire/ -- Trio Health, a leading provider [...]

- Judge denies state motion to dismiss lawsuit over non-treatment for chronic Hepatitis C - Nexus Services fights for inmate denied Constitutional rights in state prison system VERONA, Va., Aug. [...]

TAIPEI, Taiwan, April 23, 2019 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ('TaiGen') announced today that Phase III trial of the combination therapy Furaprevir - Yimitasvir for the treatment of chronic [...]

MATAWAN, N.J., June 12, 2017 /PRNewswire/ -- Copharix(TM) announces the initial launch of its innovative services designed to help improve healthcare outcomes. Copharix(TM) is a healthcare informatics and care coordination [...]

- If approved, G/P will provide an eight week once-daily, ribavirin-free treatment option for HCV patients without cirrhosis across all major genotypes - AbbVie's investigational regimen was granted Breakthrough Therapy [...]

United States Veteran Healthcare Administration in striking distance of curing the nation's largest group of people with hepatitis C BOSTON, Nov. 11, 2016 /PRNewswire/ -- Research presented this week at [...]

PCSK9 inhibitors could cost the health care system as much as $150 billion annually Underscores urgent need for strategies to control cost while ensuring patient access WOONSOCKET, R.I., Feb. 17, [...]

- Viekira Pak Will Be the Exclusive Option for Genotype 1 Hepatitis C Patients Covered by the Express Scripts National Preferred Formulary - Multi-Year Agreement Significantly Expands Affordable Access to [...]

Findings underscore ongoing need for strategies to manage treatment costs WOONSOCKET, R.I., Dec. 18, 2014 /PRNewswire/ -- The CVS Health Research Institute today released a first look at the comparative [...]

-- Studies focused on patients where there is a high unmet need today or anticipated in the near future -- BOSTON, Nov. 7, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) [...]

Reducing Failed Hep C Therapies by Half ST. LOUIS, Nov. 6, 2014 /PRNewswire/ -- The http://lab.express-scripts.com/insights/specialty-medications/harvoni-orphan-drug-pricing-for-a-nonorphan-drug Ç Harvoni and its predecessor Sovaldi Ç are unprecedented and unsustainable for the country, [...]

LONDON, July 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: https://www.reportbuyer.com/product/2076242/Hepatitis-C-Game-changing-regimens-to-revolutionise-treatment-landscape---KOL-Insight.html#utm_source=prnewswire https://www.reportbuyer.com/product/2076242/Hepatitis-C-Game-changing-regimens-to-revolutionise-treatment-landscape---KOL-Insight.html Approval of Gilead's once daily oral nucleotide inhibitor Sovaldi marks a significant step in [...]

- Results Confirm Efficacy and Safety of an All-Oral combination of Mogrovir(TM) with Ribavirin(TM) in Genotype 1, Therapy Naive HCV Patients. LOS ANGELES, July 1, 2014 /PRNewswire/ -- Canopus BioPharma [...]

ST. LOUIS, June 24, 2014 /PRNewswire/ -- http://accredo.com/ has recently launched https://itunes.apple.com/us/app/accredo-plus-c/id885883930?ls=1&mt=8 , a new iOS app that empowers hepatitis C patients to take control, better manage their treatment and [...]

SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) is pleased to announce that it has dosed the first patient in its 'first in man', [...]

-- Filing Includes Data from Treatment-Naive Patients with Advanced Fibrosis and Null Responders with All Stages of Liver Fibrosis -- RARITAN, N.J., May 7, 2014 /PRNewswire/ -- Janssen Research & [...]

ALEXANDRIA, Va., April 9, 2014 /PRNewswire/ -- The American Association for the Study of Liver Diseases (http://www.aasld.org/ ) launched ACT-First: A Practical Introduction to Liver Disease . 'ACT' stands for [...]

Presented: November 5, 2013 -- Walter E. Washington Convention Center, Washington, DC WASHINGTON, Nov. 4, 2013 /PRNewswire/ -- In this abstract to be presented at the annual meeting of the [...]

- STARTVerso (TM)1 data presented in treatment-naive patients with genotype-1 hepatitis C treated with investigational faldaprevir and pegylated interferon/ribavirin - Statistically significant viral cure rates achieved versus placebo plus PegIFN/RBV [...]

Phase 3 HCVerso (TM) trials to enroll genotype-1b patients following Phase 2b data in this population RIDGEFIELD, Conn., Jan. 17, 2013 /PRNewswire/ -- Today, http://us.boehringer-ingelheim.com/ Pharmaceuticals, Inc. announced that the [...]

- Interferon-free Hepatitis C Regimens will be Studied in Broad Patient Populations across Multiple Countries ABBOTT PARK, Ill., Nov. 13, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today released details on [...]

BEERSE, Belgium, April 19, 2012 /PRNewswire/ -- Today sees the launch of Janssen Therapeutics EMEA, a division of Janssen Pharmaceutica NV, dedicated to bringing the investigational protease inhibitor TMC435 to [...]

SAN DIEGO, Feb. 1, 2012 /PRNewswire/ --Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today [...]

**Added PSI-7977 monotherapy arm in treatment-naive patients with HCV GT1 **Added PSI-7977/RBV arm in treatment experienced patients with HCV GT2/3 **Modified previously-announced treatment regimen in HCV GT1 prior null responders [...]

PRINCETON, N.J., June 8, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, [...]

- Phase 1 combination study of a pyrimidine (PSI-7977) and purine (PSI-938) nucleotide analog in patients with chronic hepatitis C - Interim data expected in first quarter of 2011 PRINCETON, [...]

ROCHESTER, N.Y., May 13 /PRNewswire/ -- A new review on the Amazon website suggests that the natural antiviral supplement Gene-Eden may be effective in reducing the Hepatitis C viral load [...]

SINGAPORE, May 6 /PRNewswire/ -- As concerted efforts to raise disease awareness have expanded the number of diagnosed cases, the hepatitis C therapeutics market in Taiwan is beginning to witness [...]

WASHINGTON, Dec. 7 /PRNewswire-USNewswire/ -- With today's forthright and valiant announcement by Congressman Hank Johnson (D-Ga.) that he is undergoing treatment for chronic hepatitis C virus, the National Viral Hepatitis [...]

WASHINGTON, Nov. 24 /PRNewswire-USNewswire/ -- New peer-reviewed data finding that fewer than one-fifth of the nearly 4 million Americans infected with chronic hepatitis C virus have received anti-viral therapy in [...]

REALIZE is the first phase III study to evaluate a specifically targeted antiviral therapy for hepatitis C (STAT-C) across a full range of HCV-patients who failed prior treatment to current [...]

PHILADELPHIA, Nov. 28 /PRNewswire-USNewswire/ -- Data from Phase II studies published today in the New England Journal of Medicine (NEJM) report that GlaxoSmithKline's (GSK) investigational compound PROMACTA (TM) (eltrombopag) significantly [...]

- Roche Continues Commitment to Examining Treatment Options for All Patients - NUTLEY, N.J., Nov. 3 /PRNewswire/ -- Roche announced today that the company is investing more resources in treating [...]